[SCHEDULE 13G/A] Fate Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G/A reporting that they collectively hold 2,274,020.09 shares of Fate Therapeutics common stock, representing 2.0% of the class. The cover pages report shared voting power of 2,273,623.09 shares and shared dispositive power of 2,274,020.09 shares.

The filing includes a joint filing agreement (Exhibit 99.1) and an exhibit identifying Goldman Sachs & Co. LLC as a subsidiary of The Goldman Sachs Group, Inc. (Exhibit 99.2). The filing further certifies the securities are held in the ordinary course of business and not for the purpose of changing control. The statement is signed by Veronica Mupazviriwo as attorney-in-fact on behalf of both reporting persons.

Insights

Financial Analyst

TL;DR: Routine Schedule 13G/A shows a passive, 2.0% beneficial stake by Goldman Sachs entities; disclosure appears clerical and non-disruptive.

The filing reports an aggregate beneficial ownership of 2,274,020.09 shares (2.0% of the class) with nearly identical shared voting and dispositive figures. The inclusion of a joint filing agreement and an exhibit identifying the broker-dealer as a subsidiary indicates coordinated reporting between parent and subsidiary. The filing explicitly states the holdings are in the ordinary course of business and not intended to influence control, consistent with a passive disclosure under Schedule 13G/A.

Corporate Governance Expert

TL;DR: Governance impact is minimal; the report documents shared authority but affirms no intent to change issuer control.

The Schedule 13G/A documents shared voting power of 2,273,623.09 and shared dispositive power of 2,274,020.09 held by the reporting persons. Exhibit 99.1 formalizes the joint filing and Exhibit 99.2 identifies the subsidiary relationship between the reporting entities. The cover statement's certification that the securities are not held to influence control supports a neutral governance implication for the issuer.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

FATE THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

31189P102

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 31189P102

1

Names of Reporting Persons

THE GOLDMAN SACHS GROUP, INC.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,273,623.09
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,274,020.09

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,274,020.09

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.0 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP No. 31189P102

1

Names of Reporting Persons

GOLDMAN SACHS & CO. LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,273,623.09
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,274,020.09

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,274,020.09

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.0 %

12

Type of Reporting Person (See Instructions)

BD, OO, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: FATE THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 12278 Scripps Summit Dr., San Diego, X1, 92131
Item 2.
(a)	Name of person filing: THE GOLDMAN SACHS GROUP, INC.| GOLDMAN SACHS & CO. LLC
(b)	Address or principal business office or, if none, residence: The Goldman Sachs Group, Inc. 200 West Street New York, NY 10282| Goldman Sachs & Co. LLC 200 West Street New York, NY 10282
(c)	Citizenship: THE GOLDMAN SACHS GROUP, INC. - Delaware| GOLDMAN SACHS & CO. LLC - New York
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 31189P102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: See the response(s)to Item 11 on the attached cover page(s).
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit (99.2)
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

THE GOLDMAN SACHS GROUP, INC.

Signature:	Name: Veronica Mupazviriwo
Name/Title:	Attorney-in-fact
Date:	07/17/2025

GOLDMAN SACHS & CO. LLC

Signature:	Name: Veronica Mupazviriwo
Name/Title:	Attorney-in-fact
Date:	07/17/2025

Exhibit Information

EXHIBIT (99.1) JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.001 per share, of FATE THERAPEUTICS, INC. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G. Date: 07/17/2025 THE GOLDMAN SACHS GROUP, INC. By:/s/ Veronica Mupazviriwo ---------------------------------------- Name: Veronica Mupazviriwo Title: Attorney-in-fact GOLDMAN SACHS & CO. LLC By:/s/ Veronica Mupazviriwo ---------------------------------------- Name: Veronica Mupazviriwo Title: Attorney-in-fact EXHIBIT (99.2) ITEM 7 INFORMATION The securities being reported on by The Goldman Sachs Group, Inc. ("GS Group"), as a parent holding company, are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC ("Goldman Sachs"), a broker or dealer registered under Section 15 of the Act and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940. Goldman Sachs is a subsidiary of GS Group.

FAQ

What stake in Fate Therapeutics (FATE) did Goldman Sachs report?

The filing reports an aggregate beneficial ownership of 2,274,020.09 shares, representing 2.0% of Fate Therapeutics' common stock.

How much voting and dispositive power do the reporting persons have over FATE shares?

The cover pages report shared voting power of 2,273,623.09 shares and shared dispositive power of 2,274,020.09 shares.

Did the filing state the purpose of the holdings in the Schedule 13G/A for FATE?

Yes. The filing certifies the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

Which Goldman entities filed the Schedule 13G/A for FATE?

The reporting persons are The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC.

Are there exhibits attached to the filing explaining the relationship between reporting persons?

Yes. Exhibit (99.1) is a Joint Filing Agreement and Exhibit (99.2) identifies Goldman Sachs & Co. LLC as a subsidiary of The Goldman Sachs Group, Inc.